# GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

> **NCT04060342** · PHASE1 · TERMINATED · sponsor: **GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma
- Esophageal Adenocarcinoma
- Esophageal Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Triple Negative Breast Cancer
- Castration-resistant Prostate Cancer
- Microsatellite Stable Colorectal Cancer
- Non-small Cell Lung Cancer
- Small-cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** GB1275
- **DRUG:** nab-paclitaxel and gemcitabine
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT04060342
- **Lead sponsor:** GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-13
- **Primary completion:** 2022-04-11
- **Final completion:** 2022-04-11
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab.
- **Last updated:** 2022-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04060342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04060342, "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04060342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*